Should I buy or sell Windtree Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Windtree Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" WINT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WINT, but not buy additional shares or sell existing shares. View WINT analyst ratings or view top-rated stocks .

How have WINT shares performed in 2024?

Windtree Therapeutics' stock was trading at $0.7190 on January 1st, 2024. Since then, WINT stock has decreased by 41.6% and is now trading at $0.42. View the best growth stocks for 2024 here .

Are investors shorting Windtree Therapeutics?

Windtree Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 39,700 shares, an increase of 30.2% from the March 15th total of 30,500 shares. Based on an average daily volume of 249,600 shares, the short-interest ratio is presently 0.2 days. Currently, 0.5% of the shares of the company are short sold. View Windtree Therapeutics' Short Interest .

When is Windtree Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our WINT earnings forecast .

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics, Inc. (NASDAQ:WINT) released its earnings results on Monday, April, 3rd. The company reported ($13.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($10.50) by $2.51.

When did Windtree Therapeutics' stock split?

Windtree Therapeutics's stock reverse split on Thursday, February 23rd 2023. The 1-50 reverse split was announced on Thursday, February 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Windtree Therapeutics?

Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:WINT

Windtree Therapeutics (WINT) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free WINT Stock Alerts

$0.42

-0.02 (-4.55%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.41
▼
$0.44
50-Day Range: $0.31
▼
$0.44
52-Week Range: $0.28
▼
$18.48

Volume: 103,617 shs
Average Volume: 264,667 shs
Market Capitalization: $2.16 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Windtree Therapeutics alerts:

Windtree Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.54% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.52
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.34) to ($1.39) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.32 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Windtree Therapeutics.

3.0

Short Interest

Percentage of Shares Shorted
0.54% of the float of Windtree Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Windtree Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Windtree Therapeutics has recently increased by 30.16%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Windtree Therapeutics does not currently pay a dividend.
Dividend Growth
Windtree Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for WINT.

2.0

News and Social Media Coverage

News Sentiment
Windtree Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Windtree Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for WINT on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Windtree Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.54% of the stock of Windtree Therapeutics is held by insiders.
Percentage Held by Institutions
Only 29.33% of the stock of Windtree Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Windtree Therapeutics are expected to grow in the coming year, from ($4.34) to ($1.39) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Windtree Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Windtree Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Windtree Therapeutics has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Windtree Therapeutics Stock (NASDAQ:WINT)

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics, Inc. has a scientific collaboration with Chang Gung University for cardiovascular diseases of SERCA2a; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

WINT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

WINT Stock News Headlines

April 13, 2024 | americanbankingnews.com

Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Growth in Short Interest

April 9, 2024 | finanznachrichten.de

Windtree Therapeutics: Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 8, 2024 | globenewswire.com

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

February 2, 2024 | msn.com

Windtree Therapeutics Seeks Strategic Alternatives with Ladenburg Thalmann

February 1, 2024 | finance.yahoo.com

Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

January 31, 2024 | bizjournals.com

Windtree Therapeutics hires investment bank to explore M&A options

January 31, 2024 | finance.yahoo.com

Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

January 29, 2024 | benzinga.com

Windtree Therapeutics – This Biotech Inks License Deal For Lead Candidate

January 26, 2024 | finanznachrichten.de

Windtree Therapeutics Eliminates $15 Million Contingent Liability To Deerfield Management Company

January 26, 2024 | finance.yahoo.com

Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company

January 25, 2024 | benzinga.com

Windtree Therapeutics (NASDAQ: WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company

January 25, 2024 | finance.yahoo.com

Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company

January 24, 2024 | money.usnews.com

Windtree Therapeutics Inc

January 18, 2024 | msn.com

Windtree and Lee’s sign licence deal for heart failure therapy

January 18, 2024 | finance.yahoo.com

Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China

January 17, 2024 | bizjournals.com

Windtree Therapeutics signs drug licensing deal valued at up to $138M with Chinese drug company

January 17, 2024 | finance.yahoo.com

Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region

January 4, 2024 | markets.businessinsider.com

Hold Rating on Windtree Therapeutics Pending Key Istaroxime Studies

January 3, 2024 | msn.com

HC Wainwright & Co. Initiates Coverage of Windtree Therapeutics (WINT) with Neutral Recommendation

January 2, 2024 | markets.businessinsider.com

Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator

January 2, 2024 | finance.yahoo.com

Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator

December 19, 2023 | finance.yahoo.com

Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024

December 18, 2023 | finance.yahoo.com

Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

November 16, 2023 | finance.yahoo.com

Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent

November 9, 2023 | msn.com

Windtree TherapeuticS GAAP EPS of -$0.86

See More Headlines

Receive WINT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/03/2023
Today: 4/15/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:WINT
CUSIP: N/A
CIK: 946486
Web: www.windtreetx.com
Phone: (215) 488-9300
Fax: 215-488-9301
Employees: 20
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($20.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-39,210,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -274.89%
Return on Assets: -66.31%

Debt

Debt-to-Equity Ratio: 2.00
Current Ratio: 2.40
Quick Ratio: 2.40

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $12.97 per share
Price / Book: 0.03

Miscellaneous

Outstanding Shares: 5,150,000
Free Float: 5,120,000
Market Cap: $2.16 million
Optionable: Not Optionable
Beta: 0.61

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Craig E. Fraser (Age 59)
Chairman, President, CEO & Interim Principal Officer
Comp: $553.75k
Dr. Steven G. Simonson (Age 65)
Senior VP & Chief Medical Officer
Comp: $446.1k
Mr. Eric L. Curtis M.B.A. (Age 56)
Senior VP & COO
Comp: $526.25k
Ms. Jamie McAndrew (Age 43)
VP, Controller, Chief Accounting Officer & Corporate Secretary
Mr. George Cox (Age 72)
Vice President of Technical Operations
Dr. Pratap Paruchuru
Executive Director of Clinical Development
Ms. Tracy Rarick
Head of Operations & Program Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

WINT Stock Analysis - Frequently Asked Questions

Should I buy or sell Windtree Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Windtree Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" WINT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WINT, but not buy additional shares or sell existing shares.
View WINT analyst ratings or view top-rated stocks.
How have WINT shares performed in 2024?: Windtree Therapeutics' stock was trading at $0.7190 on January 1st, 2024. Since then, WINT stock has decreased by 41.6% and is now trading at $0.42.
View the best growth stocks for 2024 here.
Are investors shorting Windtree Therapeutics?: Windtree Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 39,700 shares, an increase of 30.2% from the March 15th total of 30,500 shares. Based on an average daily volume of 249,600 shares, the short-interest ratio is presently 0.2 days. Currently, 0.5% of the shares of the company are short sold.
View Windtree Therapeutics' Short Interest.
When is Windtree Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our WINT earnings forecast.

How were Windtree Therapeutics' earnings last quarter?: Windtree Therapeutics, Inc. (NASDAQ:WINT) released its earnings results on Monday, April, 3rd. The company reported ($13.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($10.50) by $2.51.
When did Windtree Therapeutics' stock split?: Windtree Therapeutics's stock reverse split on Thursday, February 23rd 2023. The 1-50 reverse split was announced on Thursday, February 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
How do I buy shares of Windtree Therapeutics?: Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:WINT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Windtree Therapeutics (WINT) Stock Price, News & Analysis

Windtree Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Windtree Therapeutics Stock (NASDAQ:WINT)

WINT Stock Price History

WINT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

WINT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™